What MicroGenDX does

MicroGenDX (legally Southwest Regional PCR Laboratory LLC dba MicroGenDX) is a CAP-accredited, CLIA-licensed clinical diagnostic laboratory headquartered in Lubbock, Texas, founded in 2008 and operating with a workforce of more than 200 employees. The company specializes in molecular diagnostics for infectious disease, combining quantitative PCR (qPCR) for antimicrobial resistance gene detection with next-generation sequencing (NGS) on the Illumina MiSeq i100 Plus platform to identify bacteria, mycobacteria, and fungi against a curated proprietary database of more than 60,000 microbial species. It reports 99.2% accuracy across 15+ years of CAP proficiency testing, delivers NGS results in 24 hours from sample receipt, and has processed more than 1 million cumulative samples while maintaining licensure to serve patients in all 50 US states.

The company's product portfolio comprises over 30 specialty testing panels spanning urology, orthopedics, infectious disease, ENT, wound care, podiatry, dentistry, pulmonology, ophthalmology, plastic surgery, and primary care, organized around a core qPCR+NGS platform with sub-brands such as DentalKEY, OptiKEY, AnimalKEY, and OrthoKEY PJI. Additional offerings include COVID-19 PCR testing ($99 per test), a combined COVID-19/Flu/RSV panel ($275), pooled COVID-19 testing ($30 per person), a recently launched Rapid H5 avian influenza test, and AI-assisted clinical interpretation tools including the Urine Pathogenicity Rating algorithm and the PJIDx diagnostic app for periprosthetic joint infection. The business generates revenue on a per-test basis through four parallel go-to-market motions: enterprise field sales targeting specialty physicians, direct-to-consumer ordering via a patient website, telemedicine partnerships (MedcallMD, CityHealth Urgent Care) that provide physician oversight, and hospital send-out services; the company also entered European distribution in April 2025 via a partnership with Germany's Labor Dr. Fenner.

MicroGenDX is a privately held company owned by CEO Rick Martin, a former Pfizer executive who acquired the laboratory in April 2017, with no disclosed institutional investors or external funding rounds. Reimbursement is supported by an AMA-approved PLA code and accepted Medicare, select Medicaid, and commercial insurance plans, alongside discounted self-pay options. Strategic relationships include research collaborations with the FDA, NASA, and CDC, as well as flagship clinical partnerships with the Rothman Orthopaedic Institute, University of Louisville Hospital, and Queen's University, supported by ENT, urology, and wound care advisory boards.

Name

MicroGenDX

Legal name

Southwest Regional PCR Laboratory, DBA MicroGen Diagnostics, LLC

Website

https://microgendx.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

101–250 employees

Short description

MicroGenDX is a CAP-accredited, CLIA-licensed clinical diagnostic laboratory offering qPCR and next-generation sequencing testing to identify microbial infections across 30-plus specialty panels, serving physicians, hospitals, and patients in all 50 US states.

Ownership category

akta.pro rank

Product category

Clinical Molecular Diagnostics

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH)

Keywords

• Clinical diagnostic testing
• Next-generation sequencing
• Microbial DNA diagnostics
• Antimicrobial resistance testing
• Molecular pathology laboratory

Headquarters

HQ city

Lubbock

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Diagnostic Testing Services: Revenue generated from qPCR and NGS testing services provided to healthcare providers and patients. Tests are billed under Medicare, select Medicaid, and commercial insurance plans. Discounted self-pay options available for uninsured patients.
2. Direct Patient Testing: Direct-to-consumer testing where patients pay out-of-pocket for COVID-19, dental, and other diagnostic tests. Prices range from $99 for COVID-19 to $249 for DentalKEY testing.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

MicroGenDX operates a CAP-accredited, CLIA-licensed clinical laboratory that performs qPCR + Next-Generation Sequencing (NGS) testing on patient specimens to identify bacteria, mycobacteria, fungi, and 17 antimicrobial resistance genes in 24 hours. The lab serves healthcare providers across urology, infectious disease, orthopedics, ENT, wound care, pulmonology, dentistry, ophthalmology, podiatry, and primary care with over 30 specialty panels (DentalKEY, OptiKEY, AnimalKEY, OrthoKEY PJI, COVID-19, COVID+FLU+RSV, Rapid H5, Women's and Men's Health panels). Patients can also order tests directly via a patient portal and through telemedicine partners.

Product overview

MicroGenDX operates a modular molecular diagnostic platform centered on qPCR + Next-Generation Sequencing (NGS) technology, offering over 30 specialized clinical diagnostic testing kits. The core qPCR+NGS platform provides 99.2% accuracy identification of all bacteria and fungi with 17 antimicrobial resistance gene detection in 24 hours. Specialty sub-brands include DentalKEY (oral health), OptiKEY (eye infections), AnimalKEY (veterinary), and OrthoKEY PJI (orthopedic infections with OR and Clinic variants). Additional modules cover COVID-19 testing ($99), COVID-19+FLU+RSV 3-in-1 ($275), Rapid H5 influenza, Women's Health, Men's Health, and pooled COVID-19 testing ($30). All tests leverage the same core sequencing infrastructure, Illumina MiSeq platform, and curated 60,000+ species database, differentiated by specimen type and clinical application.

Differentiator

Problem solved

Functional benefit

Products and services

• qPCR + NGS Testing (Core Platform) Core molecular diagnostic service combining quantitative PCR (qPCR) for antimicrobial resistance gene detection with Next-Generation Sequencing (NGS) for comprehensive microbial identification. Delivers 99.2% accuracy, identifies all bacteria and fungi, detects 17 resistance genes, and reports species relative abundance in 24 hours from sample receipt. Used by healthcare providers across more than 30 specialty panels.
• COVID-19 Testing Real-time Reverse Transcriptase PCR (rRT-PCR) assay for specific detection of SARS-CoV-2 virus. Validated using nasal swabs, sputum, and multiple specimen types. FDA EUA authorized April 2020. Priced at $99 per test with 24-48 hour turnaround. Available to providers, hospitals, and direct-to-consumer patients.
• COVID-19+FLU+RSV (3-in-1) Combined molecular test detecting COVID-19, Influenza, and RSV from a single sputum/saliva sample. Priced at $275 per patient for all three results with 24-hour turnaround. Enables rapid differential diagnosis of respiratory infections.
• Rapid H5 qPCR test for detection of H5 avian influenza A variants, including H5N1 (current bird flu strain). Designed for physician use in hospitals, clinics, and healthcare facilities. Provides rapid, accurate detection for clinical decisions and H5 influenza case management.
• DentalKEY Oral health qPCR+NGS testing panel (formerly PerioDX) for dental professionals. Detects Total 16S Bacterial Load and Total ITS Fungal Load, identifies over 60,000 microbial species via NGS, and screens for 10 resistance gene categories. Priced at $249 with sample types including floss wand extraction, saline rinse, or saliva.
• OptiKEY (Eye) Eye infection testing service using qPCR panel for Total 16S Bacterial Load and Total ITS Fungal Load. Optional additional PCR testing for Syphilis (Treponema pallidum) and Herpes Simplex (HSV-1 & HSV-2). Sample type: Swab. Currently unable to provide OptiKEY testing to NY patients pending CLEP validation.
• AnimalKEY Veterinary diagnostic testing service for animal bacterial and fungal infections using a qPCR panel for multiple infection types. Not for human use.
• OrthoKEY PJI OR Periprosthetic joint infection (PJI) diagnostic for revision orthopedic procedures. Combines synovial biomarkers (CRP, WBC, PMN%) and antimicrobial resistance gene detection in 24 hours with NGS identification of microbes from synovial fluid, implant wipe-downs, and swabs in 24 hours. Includes the PJIDx diagnostic app.
• OrthoKEY PJI Clinic Outpatient periprosthetic joint infection (PJI) diagnostic combining synovial biomarkers (CRP, WBC, PMN%) and resistance genes from an aspiration sample in 24 hours with NGS identification from synovial fluid in 24 hours. Includes the PJIDx diagnostic app.
• Women's Health Panel qPCR+NGS testing panel for women's health applications using urine and vaginal swab samples. Identifies bacterial and fungal pathogens with antimicrobial resistance gene detection. Available for office and hospital settings.
• Men's Health Panel qPCR+NGS testing panel for men's health applications using urine and semen samples. Identifies bacterial and fungal pathogens with antimicrobial resistance gene detection. Available for office and hospital settings.
• Pooled COVID-19 Testing Batch sample processing option for COVID-19 testing at $30 per person. Enables efficient high-volume testing for populations with low prevalence.
• Specialty Testing Panels Over 30 specialized clinical diagnostic testing kits across medical specialties including Infectious Disease, Microbiology, Orthopedics, Urology, ENT, Wound Care, Primary Care, Podiatry, Dentistry, Plastic Surgery, Pulmonary, and COVID-19. Each specialty has tailored qPCR+NGS panels.

Quantifiable outcome

• 99.2% accuracy in microbial identification (CAP proficiency testing)
• +4 more outcomes

Named customers8 records

Segments10 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Twelve partnerships are on record, tiered core, minor and flagship.

• Labor Dr. Fenner and ColleaguescoreChannel Partner/ Reseller/ Distributor · 15 April 2025MicroGen Diagnostics partnered with German medical laboratory Labor Dr. Fenner and Colleagues to offer rapid microbial DNA sequencing services to European customers. This partnership extends MicroGenDX's geographic reach into Europe.
• IC NetworkminorGTM or Marketing PartnerThe IC (Interstitial Cystitis) Network is a patient education organization dedicated to interstitial cystitis/bladder pain syndrome. Hosts articles about MicroGenDX testing for patients disappointed with traditional culture results.
• Live UTI FreeminorGTM or Marketing PartnerWebsite dedicated to helping people prevent, diagnose, and treat Urinary Tract Infections. Educates patients about MicroGenDX as a solution for failed culture tests and helps patients find doctors.
• NASAflagshipStrategic or Co-development PartnerCollaborated with NASA to study microbes from International Space Station as well as Mars Rover sterilization. Demonstrates advanced molecular diagnostic capabilities.
• FDAflagshipStrategic or Co-development PartnerCollaborated with FDA to study endoscope safety using MicroGenDX NGS technology. Trusted research partnership lab for FDA alongside NASA and CDC.
• CDCflagshipStrategic or Co-development PartnerTrusted research partnership laboratory for CDC alongside FDA and NASA. Collaborates on infectious disease research initiatives.
• Rothman Orthopaedic InstituteflagshipStrategic or Co-development PartnerKey research partner for landmark multicenter studies on periprosthetic joint infection diagnosis using NGS. Published studies in JBJS demonstrating MicroGenDX efficacy.
• University of Louisville HospitalcoreStrategic or Co-development PartnerOngoing research collaboration with James Snyder, PhD for mycology and infectious disease molecular diagnostics validation.
• Queen’s University (Kingston, Ontario)coreStrategic or Co-development PartnerResearch partnership with J. Curtis Nickel, MD on urinary microbiome studies and urological infection research.
• MedcallMDminorChannel Partner/ Reseller/ DistributorTelemedicine partnership providing physician oversight for COVID-19 and other diagnostic testing for patients without existing healthcare providers.
• CityHealth Urgent CareminorChannel Partner/ Reseller/ DistributorTelemedicine and urgent care partnership for COVID-19 testing services, including Hawaii travel-compliant testing.
• RTL GenomicscoreStrategic or Co-development PartnerAcquired RTL partner lab in 2021 to expand ongoing NGS research efforts in DNA sequencing. Acquisition strengthens primary research capabilities.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• BioFire Diagnostics (bioMérieux): BioFire's FilmArray syndromic PCR panels are the dominant rapid molecular infectious disease platform in US hospitals — a broader incumbent that competes with MicroGenDX's molecular infectious disease menu, particularly in respiratory and bloodstream panels.
• Quest Diagnostics: Quest Diagnostics is a national reference lab with extensive infectious disease and molecular testing services — a broad incumbent that competes for hospital and physician office send-out volume and has been expanding advanced molecular and NGS offerings.
• Labcorp: Labcorp operates one of the largest US clinical laboratory networks with broad molecular and microbiology offerings — a broad incumbent competing with MicroGenDX on hospital send-out and specialty molecular testing, particularly as it expands its NGS menu.
• Sonic Healthcare USA: Sonic Healthcare provides clinical laboratory services across the US including microbiology and molecular diagnostics — a broad incumbent with comparable specialty lab services and a large physician/hospital customer base.

Direct peers

• Accelerate Diagnostics: Accelerate Diagnostics delivers rapid phenotypic ID/AST directly from clinical samples — competing with MicroGenDX in the speed-of-microbiology space, though via a different (culture-based phenotypic) technology platform targeting the same hospital microbiology labs.
• Karius: Karius offers NGS-based cell-free DNA pathogen detection from blood, directly competing with MicroGenDX's qPCR+NGS approach for difficult-to-diagnose infections. Both target culture-negative and complex infectious disease cases with metagenomic-style sequencing.
• CosmosID: CosmosID provides microbial identification and antimicrobial resistance profiling via NGS using a proprietary curated database — directly comparable to MicroGenDX's 60,000+ species database and qPCR+NGS clinical workflow.
• Molzym: Molzym specializes in molecular pathogen detection from sterile body fluids using automated DNA extraction and PCR/sequencing workflows, overlapping with MicroGenDX's clinical molecular infectious disease testing service.
• Day Zero Diagnostics: Day Zero Diagnostics uses whole-genome sequencing for pathogen ID and antibiotic susceptibility prediction, targeting the same difficult-culture infectious disease niche as MicroGenDX, particularly bloodstream and complex infections.

Emerging players

• OpGen: OpGen develops molecular diagnostics and bioinformatics for rapid pathogen ID and antibiotic resistance prediction, with overlap to MicroGenDX's antimicrobial resistance gene detection and NGS-based identification work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/microgendx
• Facebookfacebook.com/microgendx

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MicroGenDX